PHARMACOKINETICS OF CEFODIZIME IN ELDERLY PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

被引:6
|
作者
VEYSSIER, P
DEVILLERS, A
DOMART, Y
FOURTILLAN, JB
BRYSKIER, A
PROCYK, T
机构
[1] CHU POITIERS,F-86021 POITIERS,FRANCE
[2] CTR HOSP V DUPOUY,ARGENTEUIL,FRANCE
关键词
D O I
10.1093/jac/26.suppl_C.77
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In young adults, the elimination half-life of cefodizime is 3.5—4 h. A pharmacokinetic study was performed in eight patients, aged 63 to 85 years, divided into two groups with the following creatinine clearances (group I: ≥ 50 ml/min and group II: < 30 ml/min). Cefodizime was administered as a 1.0-g iv bolus. In group I, pharmacokinetic parameters did not differ from those observed in young healthy volunteers in a previous study. In group II, the half-life was increased (3.42–7.41 h). There is a linear correlation between the creatinine clearance and total clearance. The daily dose given needs to be based not on the age of the patient but on the degree of renal impairment. In elderly patients with severe renal impairment, the daily dose should be reduced if the creatinine clearance falls below 30 ml/min. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [41] INFLUENCE OF MILD, MODERATE, AND SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF CLAZOSENTAN
    Bruderer, Shirin
    Tsvitbaum, Nahum
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1102 - 1102
  • [42] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [43] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [44] Outcomes of Patients With and Without Severe Renal Impairment Admitted with Moderate and Severe Diabetic Foot Infections
    Coye, Tyler L.
    Crisologo, Peter
    Suludere, Mehmet A.
    Lavery, Lawrence A.
    DIABETES, 2023, 72
  • [45] A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
    Swan Lin
    Jason Gong
    George C. Canas
    Peter Winkle
    Kathleen Pelletier
    Robert R. LaBadie
    Katherine Ginman
    Yazdi K. Pithavala
    European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 235 - 245
  • [46] Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment
    Chan, KCA
    Lit, LCW
    Law, ELK
    Tai, MHL
    Yung, CU
    Chan, MHM
    Lam, CWK
    CLINICAL CHEMISTRY, 2004, 50 (04) : 757 - 759
  • [47] Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment
    Ting, Clara
    Rhoten, Megan
    Dempsey, Jillian
    Nichols, Hunter
    Fanikos, John
    Ruff, Christian T.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [48] Pharmacokinetics, Safety, and Tolerability of Tanimilast Following Single Administration in Subjects With Mild, Moderate, and Severe Renal Impairment
    Emirova, A.
    Piccino, A.
    Balzano, D.
    Rizzo, E.
    Bellatti, P.
    Rostello, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [49] POPULATION PHARMACOKINETICS AND THERAPEUTIC EFFICACY ANALYSIS OF FEBUXOSTAT IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
    Hira, Daiki
    Chisaki, Yugo
    Noda, Satoshi
    Araki, HIsazumi
    Uzu, Takashi
    Maegawa, Hiroshi
    Yano, Yoshitaka
    Morita, Shin-ya
    Terada, Tomohiro
    DRUG METABOLISM REVIEWS, 2015, 47 : 224 - 225
  • [50] A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment
    Lin, Swan
    Gong, Jason
    Canas, George C.
    Winkle, Peter
    Pelletier, Kathleen
    LaBadie, Robert R.
    Ginman, Katherine
    Pithavala, Yazdi K.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (02) : 235 - 245